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Introduction
Cervical cancer is the third most common cancer diag-
nosis and the fourth leading cause of death in women
worldwide, responsible for 9% (529,800) of all new can-
cer cases and 8% (275.100) of cancer deaths in women in
2008 [1]. Cervical cancer is the most common malignancy
diagnosed in pregnancy [2, 3]. Cervical intraepithelial neo-
plasia (CIN) as a cancer precursor lesion has a ten-fold
higher incidence than cervical cancer with a peak in women
aged 25-29 years [4]. CIN is distinguished in three degrees
of severity. Non-pregnant patients with CIN 3 are treated
surgically by cervical conisation. Management guidelines
for CIN 3 for pregnant patients recommend cytologic and
colposcopic examinations every 8 to 12 weeks. Cervical
conisation is only recommended when invasive carcinoma
is suspected. In case of postpartum persistence CIN 3 is
managed with loop electrosurgical excision like in non-
pregnant women [5]. The data situation regarding conser-
vative management in pregnant patients is still sparse and
further evaluation regarding safety is needed. Furthermore
there is no knowledge about psychological effects in
women who are treated conservatively when a cancer pre-
cursor lesion is diagnosed in pregnancy. The purpose of this
investigation was to perform a case control study of preg-
nant women with severe dysplasia and non-pregnant
matched controls in order to compare postpartum regres-
sion, progression, and long-time healing rates. In addition
this study furthermore assesses the emotional impact of the
event and compares the emotional distress in pregnant and
non-pregnant patients with CIN. 
Materials and Methods
The authors performed a retrospective case control study of
consecutively treated pregnant women with severe dysplasia, de-
fined as cytologic high-grade squamous intraepithelial lesion
(HSIL) and/or histologic CIN 3. Patients were treated during the
time period from January 2000 to June 2011 in the Dysplasia Unit
of the Ludwig-Maximilians-University of Munich. Control pa-
tients with severe dysplasia were matched for the year of diagno-
sis and date of birth ± four years. Regression of dysplasia was
defined as a spontaneous improvement of high-grade dysplasia to
< CIN 3 or a negative for intraepithelial lesion or malignancy
(NILM) smear at the time of first postpartum control, progression
as worsening CIN 3 to an invasive carcinoma. In order to evalu-
ate long-time healing rates all patients were invited to the Dys-
plasia Unit for a follow-up pap smear and HPV screening at the
time of study initiation. If a patient was not able or willing to at-
tend, data was obtained from the attending gynecologist after writ-
ten consent. Long-time healing was defined as a NILM smear.
Cytology smears were classified according to the Munich nomen-
clature II and subsequently adapted to the Bethesda system (Table
1). 
To calculate the time from the first abnormal pap smear to the
diagnosis of severe dysplasia, cytology results were requested
from the patient’s attending gynecologist after written consent.
Pregnant dysplasia patients were additionally given a question-
naire concerning obstetrical data (date of birth, delivery mode,
birth weight, and complications during pregnancy). 
To evaluate the subjective psychological distress caused by the
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traumatising event of the diagnosis, all patients were asked to
complete the Impact of Event Scale-Revised (IES-R) question-
naire [3] in a German adapted version [6].
The questionnaire is composed of 22 questions and determines
the actual stress caused by an extreme event, enabling the objec-
tive comparison of different levels of stress. The patients were
asked to select one out of four possible answers for each ques-
tion. The answer “not at all” was counted with 0, “a little bit” with
1, “moderately” with 3, and “frequently” with 5 points. 
The questions are divided into three subscales: Intrusion, Avoid-
ance and Hyperarousal in which the values of the given answers
are simply summarized. The suspected diagnosis of posttraumatic
stress disorder is calculated as followed: X = (-0.02 * Intrusion)
+ (0.07 * Avoidance) + (0.15 * Hyperarousal) – 4.36. When X >
0 the suspicion of a post-traumatic stress disorder can be raised.
The minimum possible value for X is -5.06 and the maximum
value 3.69.
All women participating in the case control study signed a writ-
ten informed consent form. Protocols were approved by the local
ethical review board of the Ludwig-Maximilians-University. 
For patient demographics, risk factors, progression parameters,
and the evaluation of the questionnaire descriptive statistics were
used. Metrical normally distributed variables are represented as
mean ± standard deviation, non-normally distributed ones are de-
picted as median (quartile 1; quartile 3). P < 0.05 was considered
statistically significant, the confidence interval was defined as
95%. In order to compare metrical variables of two independent
groups, the Mann-Whitney U-Test was performed, in case of a
normal distribution the t-test was applied. The chi-square test was
used to assess statistical differences between the two groups con-
cerning given answers in the IES-R questionnaire. All statistical
tests were performed using SPSS version 19.
Results
One hundred thirteen pregnant patients with CIN 3 or
HSIL cytology were identified, of whom 52 were partici-
pated. 104 non-pregnant patients were eligible for the con-
trol group, matched by year of diagnosis of severe dysplasia
and date of birth ± four years. 44 women in the control
group took part in the study. The median patient age of both
groups was 32 years (29-35). There was no difference re-
garding the risk factors tobacco use and duration of intake
of contraceptives between the two groups (data not shown).
In the case group the initial diagnosis of dysplasia was in
42.3% before pregnancy and in 57.7% during pregnancy,
whereas 70% (n=21) were diagnosed within the first
trimester and 30% (n=9) in the second one. There was no
initial diagnosis in the last trimester.
The initial diagnosis in both groups mainly occurred as
an abnormal Pap smear. Most patients in both groups had
an initial diagnosis of dysplasia in the course of a
LSIL/HSIL or HSIL Pap smear (Table 2). In 40 pregnant
patients (76.9%) severe dysplasia was diagnosed by biopsy,
12 women (23.1%) had cytological severe dysplasia. Al-
most all patients (n= 40, 90.9%) in the control group had a
biopsy. HPV screening was performed in 98.1% of preg-
nant women and in 95.5% of controls, respectively; all
tested participants were HPV high risk positive. 
80.8% (n=42) in the pregnant group were managed by
loop electrosurgical excision eight to ten weeks after de-
livery while in the control group a conisation was per-
formed in every patient (n=44). One pregnant patient was
lost to follow-up. There was no need for loop electrosur-
gical excision in nine patients of the pregnant group
(17.3%) due to spontaneous regression. In these patients
the diagnosis of regression was confirmed by biopsy in
five cases, showing CIN 1 in two cases and a benign result
in three cases, whereas the remaining four women had cy-
tologic regression (NILM) with no biopsy performed. In
five postpartum patients with loop conisation, regression




Negative for intraepithelial lesions and
malignancy (NILM)
Pap I, Pap II
Atypical squamous cells of
undetermined significance (ASC-US)
Pap IIw
Atypical squamous cells – 
cannot exclude HSIL (ASC-H)/
Atypical glandular cells not
Pap III
otherwise specified (AGC-NOS)
Low grade squamous intraepithelial lesion (LSIL)/
High grade squamous intraepithelial lesion (HSIL)
Pap IIID
High grade squamous intraepithelial lesion (HSIL) Pap IVa, Pap IVb
Table 2. — Pap smear and histology results at time of ini-
tial diagnosis.
Group Pap smear




CIN1 0 0 1 0 1
CIN2 0 0 1 0 1
CIN3 0 0 2 5 7
No biopsy 2 4 15 22 43
Total 2 4 19 27 52
Control
Histology
CIN1 0 0 0 0 0
CIN2 0 0 0 1 1
CIN3 0 0 1 2 3
No biopsy 4 3 22 11 40
Total 4 3 23 14 44
Both
Histology
CIN1 0 0 1 0 1
CIN2 0 0 1 1 2
CIN3 0 0 3 7 10
No biopsy 6 7 37 33 83
Total 6 7 42 41 96
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was seen in the cone specimen, showing CIN 2 in one case
and a completely benign result in four cases (Table 3).
Overall 14 women in the pregnant group turned out to have
a spontaneous regression of high-grade dysplasia, 12 pa-
tients in the postpartum period, and two even antepartum.
There was no statistical significant difference in the re-
gression rates with regards to the mode of delivery (data
not shown).
Only one patient in the control group showed sponta-
neous regression with a benign histology in the conisation
specimen, while all of the remaining 43 women had a CIN
3 in the conisation specimen (Fisher’s exact test: p = 0.01).
There was no progression to invasive carcinoma within
both groups. 
After a median follow-up of 41.61 (22.67–98.14) months
the healing rate, defined as a NILM Pap smear, was 88.2%
in the case group. Four women still appeared to have an ab-
normal cytology result, with no patient showing LSIL or
HSIL cytology. Three patients were lost to follow-up.
Twelve of 14 patients with postpartum regression were
healed of dysplasia and two remained with ASC-US/ASC-
H Pap smear. The control group showed a healing rate of
88.3% after a median follow up of 36.39 (18.33–61.68)
months. Five patients remained with an abnormal Pap
smear, whereas no patient had HSIL cytology and only one
patient showed LSIL/HSIL cytology. One control patient
was lost to follow up (Table 4). Twenty-seven women of
the case group had a current HPV test, of which 88.9%
were high risk negative. 81.8% of the 33 tested women in
the control group were HPV high risk negative. There was
no significant difference between the two groups (Fisher’s
exact test: p = 0.442).
88.5% (46/52) of IES-R questionnaires sent out to the
group of pregnant women were sent back completed; the
control group returned 100% (44/44). Twenty-four women,
14 cases and ten controls, crossed out the questionnaire
meaning that they were not stressed anymore. The follow-
ing incidents were named as the primary endpoint of not
feeling distressed by the dysplasia any longer: “After the
first non-pathological pap smear” (cases: n=5/35.7%; con-
trols: n=3/30%), “I never felt distressed by the incident”
(cases: n=1/7,1%; controls: n=1/10%), and “After the cone
biopsy” (cases: n=1/7.1%; controls: n=0). Seven cases
(50%) and six controls (60%) crossed out the questionnaire
but made no statement.
All three subscales showed statistically significant dif-
ferences between the two compared groups. Intrusion in
total showed significantly different answers (Mann-Whit-
ney U-Test: p = 0.016), notably to the questions 3, 9, 14,
and 20 (Chi²-Test q3: p = 0.033; q9: p = 0.005; q14: p =
0.024; q20: p = 0.009). The group of non-pregnant women
compared to the group of pregnant women was less able to
overcome the occurrence of high-grade dysplasia, with pic-
tures popping into their minds, dreaming about it, and being
reminded of it by other things. The subscale Avoidance also
showed a significant difference between the two groups
(Mann-Whitney U-Test: p = 0.047). The control group in
particular tried not to talk or think about it, in comparison
to the pregnant women (Chi²-Test q11: p = 0.003; q22: p =
0.038).
Controls showed higher values of Hyperarousal than
cases (Mann-Whitney U-Test: p = 0.039). Particularly
questions 19 and 21 (“Reminders of it caused me to have
physical reactions, such as sweating, trouble breathing,
nausea, or a heart palpitations”; “I felt watchful and on-
guard”) display a significant difference between the groups
(Chi²-Test q19: p = 0.017; q21: p = 0.019).
Calculations of the posttraumatic stress disorder value X
show a total mean of -3.2 ± 1.5 and a median of -3.9 (-4.4;
-2.4). Cases have a significantly different median compared
to the controls (Mann-Whitney U-Test: p = 0.037) (Table




Group n NILM Benign CIN1 CIN2 Total CIN3 total
Case
Conisation 42 0 4 0 1 5 37 37
No conisation 9 4 3 2 0 9 0 0
Lost to follow-up 1
Total 52 4 7 2 1 14 37 37
Control
Conisation 44 0 1 0 0 1 43 43
No conisation 0 0 0 0 0 0 0 0
Total 44 0 1 0 0 1 43 43
Table 4. — Healing rates.
Group NILM ASC-US/ ASC-H/ LSIL/ HSIL Lost to 
ASC-H ASC-NOS HSIL follow-up
Case
n 45 3 1 0 0 3
in % 88.2 6.7 2.2 0 0 6.7
Control
n 38 3 1 1 0 1
in % 88.3 7.9 2.6 2.6 2.6
Table 5. — Calculations of the posttraumatic stress disor-
der value.
IES-R Pregnant group Control group Statistics
N=46 N=44 Mann-Whitney
Median (Quartiles) U Test U-Test
Intrusion 1.0 (0.0; 7.75) 6.5 (0.0; 17.0) p = 0.016*
Avoidance 3.0 (0.0; 10.0) 6.5 (0.0; 20.0) p = 0.047*
Hyperarousal 0.0 (0.0; 5.0) 3.0 (0.0; 13.0) p = 0.039*
Distress-value X -4.1 (-4.4; -3.1) -3.4 (-4.4; -1.7) p = 0.037*
Mean (±SD)
-3.6 ± 1.2 -2.8 ± 1.7
*p < 0.05.
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5). Six patients showed a posttraumatic stress disorder
value of X > 0 (Cases: 1; Controls: 5). Calculated values
were between 0.10 and 0.72. Except for one control, all
women with elevated distress values were cured from cer-
vical dysplasia until the end of data collection. 
Discussion
In this retrospective case-control study, the authors
analysed oncological safety in pregnant and non-pregnant
patients with either cytologically or histologically proven
high-grade dysplasia. The present data support the thesis
that non-surgically management in pregnant patients is safe
since no progression to cervical cancer occurred. 
Several reasons justify a conservative approach in preg-
nant patients with CIN 3. First of all, surgical manipulation
of the cervix can result in preterm contractions followed by
premature birth. Higher rates of preterm birth after cervical
conisation are well known even if surgery is performed in
non-pregnant patients [7-10]. Secondly, existing data sug-
gest a high spontaneous regression rate of cervical dyspla-
sia in postpartum patients and progression rates to cervical
cancer are low [11]. 
In this study 41 (78.8%) pregnant patients received a con-
isation eight to ten weeks after delivery showing regression
in five patients. In nine women regression was confirmed
by biopsy or cytology without a need for operation, show-
ing a total regression rate in the pregnant group of 26.9%.
Similar results were published in a prospective study for
CIN 1 in pregnant and non-pregnant patients [12], as well
as for patients with carcinoma in situ during pregnancy
[13]. Other groups published even higher postpartum re-
gression rates between 47.2% and 70.0% 6 to 12 weeks
after delivery [12, 14-16]. Partially in these studies CIN 2
and 3 patients were evaluated together. Considering higher
regression rates of CIN 2 lesions [17] could be part of the
difference in overall higher regressions rates.
Long-time healing rates of dysplasia are high in both
groups showing no differences between pregnant and non-
pregnant patients. Even in patients with spontaneous re-
gression, 12 out of 14 women show a regular smear result
and two display only minor changes in their final cytolog-
ical result. These results are further supported by a high
elimination rate of high-risk HPV types in both groups
(88.9% case group, 81.8% control groups). A negative high
risk HPV test after conisation is a known test of cure [18]
and generally regarded as evidence of successful treatment.
The negative predictive value for a negative HPV test after
a cone biopsy is between 92% [15] and 100% [19-23] and
successful treatment usually leads to an elimination of the
virus [24-27]. 
In anticipation of high emotional stress in pregnant pa-
tients diagnosed with CIN 3 and consecutive serial con-
trols, the present authors were surprised that in this study
the burden of dysplasia was not higher in the case group.
Surprisingly there is even a higher number of patients with
elevated post-traumatic stress values in the control group
(n=5 control, n=1 case group). Still there are only 30.4%
of the cases and 22.7% of the controls who denied an actual
burden of dysplasia. 
Limitations of the present study include its retrospective
design and the numeric dimension of the study population.
A high percentage of patients did not participate in the
study (42% control group/ 46% pregnant group) mainly due
to avoidance of recurrent emotional stressors, which could
have biased the results as well. Since questionnaires were
sometimes completed a long time after the initial diagnosis
of severe dysplasia, results are difficult to interpret and
probably do not reproduce the actual “real” stress after con-
frontation with the diagnosis in all cases. 
The study confirms that an expectative management of
high-grade cervical dysplasia in pregnancy is safe, as no
progression to invasive cancer occurred. This is congruent
with other data [12, 15, 28] and in accordance to official
guidelines and recommendations [5]. 
Taking into account the high postpartum regression rates,
a prolongation of the postpartum observation period could
represent a reasonable option. Prospective data to answer
this question is needed. The authors suggest histological
confirmation in every postpartum patient before planning a
conisation, since 12.2% of pregnant patients already
showed regression in their conisation specimen. The exact
mechanisms for higher postpartum regression rates are not
entirely understood. There are different theories existing
like the induction of viral activation in women already la-
tently infected with HPV due to hormonal changes in preg-
nancy leading to cervical dysplasia which then regresses
after pregnancy. Additionally an impaired immune system
during pregnancy could be reactivated postpartum [29-31].
Concerning the influence of vaginal birth on regression
rates, there are different opinions in the literature [32-34].
In the present study the authors could not detect a statisti-
cally significant relation between mode of delivery and re-
gression rates. 
Conclusion
The present study supports the expectant management of
pregnant patients with dysplasia. It might even be consid-
ered to wait longer than 8 to 12 weeks postpartum before a
loop electrosurgical excision procedure is performed. Since
distress levels are low in general and surprisingly even
lower in pregnant patients, a prolongation of the observa-
tional period seems to be feasible also from a psychologi-
cal point of view. From the present authors’ knowledge,
these are the first published data of a long-time follow-up
of severe dysplasia in pregnancy. 
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